These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20673341)

  • 21. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease.
    Lahiri DK; Farlow MR; Hintz N; Utsuki T; Greig NH
    Acta Neurol Scand Suppl; 2000; 176():60-7. PubMed ID: 11273593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease.
    Sjölander A; Zetterberg H; Andreasson U; Minthon L; Blennow K
    Mol Neurodegener; 2010 Sep; 5():37. PubMed ID: 20849576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury.
    Olsson A; Csajbok L; Ost M; Höglund K; Nylén K; Rosengren L; Nellgård B; Blennow K
    J Neurol; 2004 Jul; 251(7):870-6. PubMed ID: 15258792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    van Waalwijk van Doorn LJC; Ghafoorian M; van Leijsen EMC; Claassen JAHR; Arighi A; Bozzali M; Cannas J; Cavedo E; Eusebi P; Farotti L; Fenoglio C; Fortea J; Frisoni GB; Galimberti D; Greco V; Herukka SK; Liu Y; Lleó A; de Mendonça A; Nobili FM; Parnetti L; Picco A; Pikkarainen M; Salvadori N; Scarpini E; Soininen H; Tarducci R; Urbani A; Vilaplana E; Meulenbroek O; Platel B; Verbeek MM; Kuiperij HB
    J Alzheimers Dis; 2021; 79(1):163-175. PubMed ID: 33252070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frontal white matter lesions in Alzheimer's disease are associated with both small vessel disease and AD-associated cortical pathology.
    McAleese KE; Miah M; Graham S; Hadfield GM; Walker L; Johnson M; Colloby SJ; Thomas AJ; DeCarli C; Koss D; Attems J
    Acta Neuropathol; 2021 Dec; 142(6):937-950. PubMed ID: 34608542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low Prevalence of Mixed Dementia in a Cohort of 2,000 Elderly Patients in a Memory Clinic Setting.
    Claus JJ; Staekenborg SS; Roorda JJ; Stevens M; Herderschee D; van Maarschalkerweerd W; Schuurmans L; Tielkes CE; Koster P; Bavinck C; Scheltens P
    J Alzheimers Dis; 2016; 50(3):797-806. PubMed ID: 26757192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein.
    Sjögren M; Gustafsson K; Syversen S; Olsson A; Edman A; Davidsson P; Wallin A; Blennow K
    Dement Geriatr Cogn Disord; 2003; 16(1):25-30. PubMed ID: 12714796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease.
    Almdahl IS; Lauridsen C; Selnes P; Kalheim LF; Coello C; Gajdzik B; Møller I; Wettergreen M; Grambaite R; Bjørnerud A; Bråthen G; Sando SB; White LR; Fladby T
    Front Aging Neurosci; 2017; 9():9. PubMed ID: 28223932
    [No Abstract]   [Full Text] [Related]  

  • 30. Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation.
    Almkvist O; Basun H; Wagner SL; Rowe BA; Wahlund LO; Lannfelt L
    Arch Neurol; 1997 May; 54(5):641-4. PubMed ID: 9152122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity.
    Hock C; Golombowski S; Müller-Spahn F; Naser W; Beyreuther K; Mönning U; Schenk D; Vigo-Pelfrey C; Bush AM; Moir R; Tanzi RE; Growdon JH; Nitsch RM
    Eur Neurol; 1998; 39(2):111-8. PubMed ID: 9520072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between white matter lesions and cerebral Aβ burden.
    Yi HA; Won KS; Chang HW; Kim HW
    PLoS One; 2018; 13(9):e0204313. PubMed ID: 30248123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.
    Zetterberg H; Andreasson U; Hansson O; Wu G; Sankaranarayanan S; Andersson ME; Buchhave P; Londos E; Umek RM; Minthon L; Simon AJ; Blennow K
    Arch Neurol; 2008 Aug; 65(8):1102-7. PubMed ID: 18695061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Homocysteine metabolism is associated with cerebrospinal fluid levels of soluble amyloid precursor protein and amyloid beta.
    Oikonomidi A; Lewczuk P; Kornhuber J; Smulders Y; Linnebank M; Semmler A; Popp J
    J Neurochem; 2016 Oct; 139(2):324-332. PubMed ID: 27507672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How much do focal infarcts distort white matter lesions and global cerebral atrophy measures?
    Wang X; Valdés Hernández MC; Doubal F; Chappell FM; Wardlaw JM
    Cerebrovasc Dis; 2012; 34(5-6):336-42. PubMed ID: 23154746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re-evaluation of soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for early diagnosis of dementia disorders.
    Araki W; Hattori K; Kanemaru K; Yokoi Y; Omachi Y; Takano H; Sakata M; Yoshida S; Tsukamoto T; Murata M; Saito Y; Kunugi H; Goto YI; Nagaoka U; Nagao M; Komori T; Arima K; Ishii K; Murayama S; Matsuda H; Tachimori H; Araki YM; Mizusawa H
    Biomark Res; 2017; 5():28. PubMed ID: 29018524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelets and Alzheimer's disease: Potential of APP as a biomarker.
    Evin G; Li QX
    World J Psychiatry; 2012 Dec; 2(6):102-13. PubMed ID: 24175176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beta-secretase-cleaved amyloid precursor protein in Alzheimer brain: a morphologic study.
    Sennvik K; Bogdanovic N; Volkmann I; Fastbom J; Benedikz E
    J Cell Mol Med; 2004; 8(1):127-34. PubMed ID: 15090268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.
    Brinkmalm G; Brinkmalm A; Bourgeois P; Persson R; Hansson O; Portelius E; Mercken M; Andreasson U; Parent S; Lipari F; Ohrfelt A; Bjerke M; Minthon L; Zetterberg H; Blennow K; Nutu M
    Brain Res; 2013 Jun; 1513():117-26. PubMed ID: 23541617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.